학술논문
Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo
Document Type
Article
Author
Source
In: Kidney International . (Kidney International, April 2023, 103(4):772-781)
Subject
Language
English
ISSN
15231755
00852538
00852538